HRT Home  |  Get Prescriptions  |  HRT Videos  |  HRT News  |  HGH Therapy  |  Testosterone Therapy  |  Site Map  |  Contact us    


HRT getting started

HGH categories

HGH overview

HGH replacement

HGH scams



Take the first step by contacting us for a free consultation. Your information will remain confidential. * Indicates required field.
USA Citizens and Residents Only, Must be At least 30.
*Your Name:
*Day Phone:
*Evening Phone:
*Your Email:
*Confirm Email:
*Contact Time:
*Confirm Age Over 30:
*Confirm USA Citizen:
*Enter Code:
Please Fill In Above Details

Today is Saturday, May 19, 2012

SEROSTIM® HGH: Human Growth Hormone Injections Product

SEROSTIM®:

Serono offers Serostim® [somatropin (rDNA origin) for injection], the only growth hormone approved by the U.S. Food and Drug Administration for the treatment of HIV-associated wasting or cachexia. Through SeroCare®, Serono offers comprehensive support to healthcare providers and patients including education and appropriate access to care and treatment.

Serostim® (recombinant human growth hormone) works by interacting with specific cells to restore and build lean body mass (LBM). LBM includes muscle, organ tissue (excluding fat), and body fluids.

It is the only growth hormone approved by the U.S. Food and Drug Administration for the treatment of AIDS wasting or cachexia. Serostim® is mammalian cell-derived and produced using recombinant technology.

Clinical trials show that Serostim® has been effective in the treatment of AIDS wasting or cachexia. FDA approval is based on clinical studies up to 12 weeks in duration that analyzed body weight and lean body mass as an intermediate measure of Serostim®'s efficacy for AIDS wasting. A further study is underway to evaluate the full impact of Serostim® on patients' physical endurance and quality of life.

Serostim® must be used in conjunction with antiretroviral therapy. 76% of patients evaluated at week 2 of treatment had weight gain. Patients who continue to lose weight at week 2 should be reevaluated for concurrent opportunistic infections or other clinical events. The recommended duration of treatment is 12 weeks. No significant additional treatment benefit was observed in patients receiving therapy beyond 12 weeks. There are no data available from studies for patients who start, stop and restart treatment.
02 Apr 2008






HGH introduction

HGH solutions

HGH effects

HGH research

HGH regional

HGH topics

HGH tests

HGH summary



Copyright © 2007, 2008, 2009, 2010 HGH, HRT Medical Solutions Network

By using this Site you acknowledge and agree to the terms of use, privacy policy and legal disclaimer.